MindWalk (NASDAQ:HYFT – Get Free Report) and Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.
Risk & Volatility
MindWalk has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for MindWalk and Adaptive Biotechnologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MindWalk | 1 | 1 | 2 | 1 | 2.60 |
| Adaptive Biotechnologies | 1 | 1 | 6 | 0 | 2.62 |
Profitability
This table compares MindWalk and Adaptive Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MindWalk | -105.11% | -133.26% | -77.78% |
| Adaptive Biotechnologies | -20.73% | -36.81% | -13.77% |
Institutional & Insider Ownership
6.7% of MindWalk shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares MindWalk and Adaptive Biotechnologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MindWalk | $11.24 million | 6.23 | -$10.11 million | ($0.26) | -5.77 |
| Adaptive Biotechnologies | $276.98 million | 15.14 | -$59.50 million | ($0.41) | -64.10 |
MindWalk has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.
Summary
Adaptive Biotechnologies beats MindWalk on 9 of the 15 factors compared between the two stocks.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Receive News & Ratings for MindWalk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MindWalk and related companies with MarketBeat.com's FREE daily email newsletter.
